Over-Expression of Catalase in Myeloid Cells Confers Acute Protection Following Myocardial Infarction

E. Bernadette Cabigas, Emory University
Inthirai Somasuntharam, Emory University
Milton E. Brown, Emory University
Pao Lin Che, Emory University
Karl D. Pendergrass, Emory University
Bryce Chiang, Emory University
W Robert Taylor, Emory University
Michael Davis, Emory University

Journal Title: International Journal of Molecular Sciences
Volume: Volume 15, Number 5
Publisher: MDPI | 2014-05-21, Pages 9036-9050
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.3390/ijms15059036
Permanent URL: https://pid.emory.edu/ark:/25593/s5k6q

Final published version: http://dx.doi.org/10.3390/ijms15059036

Copyright information:
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/).

Accessed April 28, 2019 11:28 AM EDT
Over-Expression of Catalase in Myeloid Cells Confers Acute Protection Following Myocardial Infarction

E. Bernadette Cabigas 1,2, Inthirai Somasuntharam 1,2, Milton E. Brown 1,2, Pao Lin Che 1,2, Karl D. Pendergrass 1,2, Bryce Chiang 1, W. Robert Taylor 1,2 and Michael E. Davis 1,2,3,*

1 Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA 30322, USA; E-Mails: bgcab@yahoo.com (E.B.C.); inthirai3@gatech.edu (I.S.); mebrow5@emory.edu (M.E.B.); paolin.che@gmail.com (P.L.C.); kpdb35@hotmail.com (K.D.P.); bryce.chiang@emory.edu (B.C.); w.robert.taylor@emory.edu (W.R.T.)

2 Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30322, USA

3 Emory Children’s Center for Cardiovascular Biology, Children’s Healthcare of Atlanta, Atlanta, GA 30322, USA

* Author to whom correspondence should be addressed; E-Mail: michael.davis@bme.emory.edu; Tel.: +1-404-727-9875; Fax: +1-404-727-9873.

Received: 17 April 2014; in revised form: 12 May 2014 / Accepted: 14 May 2014 / Published: 21 May 2014

Abstract: Cardiovascular disease is the leading cause of death in the United States and new treatment options are greatly needed. Oxidative stress is increased following myocardial infarction and levels of antioxidants decrease, causing imbalance that leads to dysfunction. Therapy involving catalase, the endogenous scavenger of hydrogen peroxide ($\text{H}_2\text{O}_2$), has been met with mixed results. When over-expressed in cardiomyocytes from birth, catalase improves function following injury. When expressed in the same cells in an inducible manner, catalase showed a time-dependent response with no acute benefit, but a chronic benefit due to altered remodeling. In myeloid cells, catalase over-expression reduced angiogenesis during hindlimb ischemia and prevented monocyte migration. In the present study, due to the large inflammatory response following infarction, we examined myeloid-specific catalase over-expression on post-infarct healing. We found a significant increase in catalase levels following infarction that led to a decrease in $\text{H}_2\text{O}_2$ levels, leading to improved acute function. This increase in function could be attributed to reduced infarct size and improved angiogenesis. Despite these initial improvements, there was no improvement in chronic function, likely due to increased fibrosis. These data combined...
with what has been previously shown underscore the need for temporal, cell-specific catalase delivery as a potential therapeutic option.

**Keywords:** oxidative stress; myocardial infarction; antioxidant therapy

### 1. Introduction

Myocardial infarction affects millions of patients annually and leads to heart failure, for which there is no cure [1]. Following ischemic injury in the heart, there is an overproduction of reactive oxygen species (ROS) that leads to tissue damage, fibrosis, prevents angiogenesis, and limits regeneration [2–5]. Of the ROS, the two major species implicated in these processes are superoxide and hydrogen peroxide (H$_2$O$_2$). Both are increased following infarction and levels of their endogenous scavengers progressively decrease [6,7]. Catalase catalyzes the conversion of H$_2$O$_2$ to water and oxygen and therefore renders it less toxic to cells. It is one of the most important peroxidases in the myocardium, potentially making up 80% of all peroxidase activity in cardiomyocytes [8]. Following ischemic injury in the myocardium, there are mixed results of the therapeutic potential of catalase. Delivery of catalase was shown to protect both by itself, and when used in combination with superoxide dismutase [9–11]. In other studies catalase was shown to have no benefit, thus there is much confusion on the effects of catalase as a potential therapeutic intervention [12–14].

Adding to this controversy is the finding that, in small amounts, H$_2$O$_2$ acts to initiate a cascade of protective pathways that is activated during oxidative stress [15]. In many cell types, H$_2$O$_2$ is required for normal function and excessive amounts can even promote cardiogenic differentiation of stem cells [16,17]. When catalase was over-expressed in mouse hearts from birth, there was a significant improvement in cardiac function following infarction as compared to their wild-type littermates [18,19]. When catalase was over-expressed in cardiomyocytes in an inducible manner, no acute effect was seen, though cardiac function improved chronically due to altered remodeling, indicating the need for temporal management [20]. Recent data demonstrated that when H$_2$O$_2$ is absent in myeloid cells (due to targeted over-expression of catalase), macrophage recruitment and infiltration, as well as angiogenesis were impaired in a model of hindlimb ischemia [21]. Thus it would appear that the role of catalase is both time- and cell-specific and these could all lead to conflicts in therapeutic efficacy depending on protein *versus* gene delivery, and localization effects.

Given previous opposing effects of cardiomyocyte-specific catalase over-expression, and the potential role of inflammatory cell-derived H$_2$O$_2$ in the ischemic healing process, this study sought to determine the role of myeloid-specific over-expression of catalase on post-infarct healing. Mice over-expressing human catalase under control of a myeloid-specific promoter were subjected to myocardial infarction and both acute and chronic healing were determined. Potential mechanisms demonstrated a role for both alterations in angiogenesis, and fibrosis, and also revealed cell-specific responses in the context of prior studies.
2. Results and Discussion

2.1. Hydrogen Peroxide Production Reduced in Tg\(^{\text{MLC-CAT}}\) Mice Following Myocardial Infarction (MI)

To determine if levels of cardiac hydrogen peroxide (H\(_2\)O\(_2\)) production following MI differed in Tg\(^{\text{MLC-CAT}}\) mice, Amplex Red assay was performed using left ventricular tissue and normalized to total tissue weight. H\(_2\)O\(_2\) levels were significantly elevated at both 7- \((p = 0.001)\) and 21-days \((p < 0.0001)\) post-infarction in wild-type (WT) mice compared with sham operated controls. Tg\(^{\text{MLC-CAT}}\) mice demonstrated a significant decrease in H\(_2\)O\(_2\) production compared to their WT littermates at both 7 and 21 days \((142.0 \pm 34.8 \text{ vs. } 16.1 \pm 6.7 \text{ nM/mg} \text{ and } 139.4 \pm 25.3 \text{ vs. } 40.4 \pm 10.6 \text{ nM/mg}, \text{ respectively}; p < 0.01; \text{ Figure 1}).

**Figure 1.** Left ventricular H\(_2\)O\(_2\) production significantly decreased in Tg\(^{\text{MLC-CAT}}\) mice as compared to wild-type (WT) mice. Measurement of H\(_2\)O\(_2\) production using Amplex red assay demonstrated a significant increase in H\(_2\)O\(_2\) levels at both (A) 7 and (B) 21 days in WT mice vs. sham controls. Tg\(^{\text{MLC-CAT}}\) mice had significantly less production of H\(_2\)O\(_2\). Values are mean ± SEM; \(n = 5–6\) per group ** \(p < 0.01\) and *** \(p < 0.001\) respectively; Analysis of variance (ANOVA) followed by Bonferroni post-test.

2.2. Catalase and Peroxidase Activity Significantly Increased in Tg\(^{\text{MLC-CAT}}\) Mice

To determine if catalase activity corresponded with the diminished levels of H\(_2\)O\(_2\) production observed in Tg\(^{\text{MLC-CAT}}\) mice, decomposition of H\(_2\)O\(_2\) was measured in left ventricular protein homogenates. Catalase activity was increased at 7 days post-infarction \((p = 0.001)\) in Tg\(^{\text{MLC-CAT}}\) mice as compared to WT littermates \((9.1 \pm 1.9 \text{ vs. } 1.2 \pm 0.8 \text{ U/mg}; p < 0.05; \text{ Figure 2A,B}). At 21 days post-infarction, there were no significant changes in any group, though mice subjected to MI had a decreased trend. To determine if other peroxidase activity was altered, decomposition of H\(_2\)O\(_2\) that was not inhibited by 3-AT (a catalase inhibitor) was determined. There was a significant increase \((p = 0.002)\) in non-catalase peroxidase activity in Tg\(^{\text{MLC-CAT}}\) mice subjected to MI as compared to WT mice \((22.3 \pm 1.1 \text{ vs. } 17.4 \pm 0.5 \text{ U/mg}; p < 0.05; \text{ Figure 2C}).
Figure 2. Catalase activity acutely increased in Tg(MLC−CAT) mice as compared to WT mice. (A) Catalase activity was significantly increased at 7 days following myocardial infarction in Tg(MLC−CAT) mice as compared to WT mice. This increase in activity was also significant as compared to sham operated animals. Values are mean ± SEM; n = 5 per group; ** p < 0.01 ANOVA followed by Bonferroni post-test; (B) At 21 days, catalase activity in Tg(MLC−CAT) mice showed no significant difference from WT mice activity levels. Values are mean ± SEM; n = 5–7 per group; (C) Non-catalase peroxidase activity was significantly increased in Tg(MLC−CAT) mice as compared to WT mice at 21 days. Values are mean ± SEM; n = 5–8 per group; * p < 0.05 ANOVA followed by Bonferroni post-test.

2.3. Catalase Increased in CD45+ Cells in Tg(MLC−CAT) Mice Following Infarction

To determine the cell type responsible for the difference in catalase activity, CD45+ cells were isolated from the left-ventricular tissue 7 days following infarction. Figure 3A,B shows a representative cell sorting image used to collect CD45+ cells. Catalase activity was measured in both CD45+ and CD45− fractions in WT and Tg(MLC−CAT) mice. While there was no change in catalase activity in WT mice, there was a 3-fold increase in the CD45+ fraction (Figure 3C) in Tg(MLC−CAT) mice compared to the CD45− fraction. The CD45+ fraction of Tg(MLC−CAT) mice also had higher activity than that of WT mice.
Figure 3. Catalase activity increased in CD45<sup>+</sup> cells in Tg<sup>(MLC−CAT)</sup> mice. Cells were isolated from the left-ventricle 7 days following infarction and collected for analysis of catalase activity. (A,B) Representative cell sorting images showing the fraction of CD45<sup>+</sup> cells that were collected did not differ between groups (rectangle area denotes CD45<sup>+</sup> gate); (C) Catalase activity in isolated cells demonstrated a trend for increased activity only in CD45<sup>+</sup> cells of Tg<sup>(MLC−CAT)</sup> mice while CD45<sup>−</sup> cells showed no increase. Data are expressed as U/mg protein from pooled samples (n = 3 per group).

2.4. Acute Function Is Improved in Tg<sup>(MLC−CAT)</sup> Mice Following Infarction

To determine differences in acute ventricular function following permanent ligation, echocardiography was performed 7 days following injury. There was a significant improvement in ejection fraction (EF; p = 0.0002) and fractional shortening (FS; p = 0.0002) in Tg<sup>(MLC−CAT)</sup> mice compared to their WT littermates at 7 days post-infarction (EF 63.7% ± 1.8% vs. 48.2% ± 0.8%; p < 0.05; FS 33.2% ± 2.6% vs. 24.5% ± 1.4%; p < 0.05). Additionally, WT mice demonstrated significant decreases in function with infarction (p < 0.001) in both indices, while Tg<sup>(MLC−CAT)</sup> mice had no significant decrease with injury (Figure 4A,B). To determine chronic changes in function, echocardiography was performed at 21 days following injury. There were no significant differences between WT and Tg<sup>(MLC−CAT)</sup> mice in either EF or FS at this time point (Figure 4C,D).
Figure 4. Ventricular function acutely improved in Tg\textsuperscript{(MLC–CAT)} mice. Echocardiographic studies demonstrated: (A) At 7 days following myocardial infarction, percent ejection fraction (\% ejection fraction (EF)) was significantly increased in Tg\textsuperscript{(MLC–CAT)} mice as compared to WT mice. Values are mean ± SEM; \( n \geq 6 \) per group; * \( p < 0.05 \), ** \( p < 0.01 \) ANOVA followed by Bonferroni post-test; (B) At 7 days following myocardial infarction, percent fractional shortening (\% fractional shortening (FS\%)) was significantly increased in Tg\textsuperscript{(MLC–CAT)} mice as compared to WT mice. Values are mean ± SEM; \( n \geq 6 \) per group; * \( p < 0.05 \), *** \( p < 0.001 \) ANOVA followed by Bonferroni post-test; (C) At 21 days following myocardial infarction, %EF showed no significant difference between Tg\textsuperscript{(MLC–CAT)} mice as compared to WT mice. Values are mean ± SEM; \( n = 6–9 \) per group; ** \( p < 0.01 \), *** \( p < 0.001 \) ANOVA followed by Bonferroni post-test; (D) At 21 days following myocardial infarction, FS\% showed no significant difference between Tg\textsuperscript{(MLC–CAT)} mice as compared to WT mice. Values are mean ± SEM; \( n = 7–10 \) per group; *** \( p < 0.001 \) ANOVA followed by Bonferroni post-test.

2.5. Infarct Size Significantly Decreased in Tg\textsuperscript{(MLC–CAT)} Mice

To determine the degree of tissue damage, infarct size was compared between Tg\textsuperscript{(MLC–CAT)} mice and their WT littermates 72 h following injury. While there were no changes in area-at-risk, there was a significant decrease in infarct size in Tg\textsuperscript{(MLC–CAT)} mice vs. WT controls (38.1% ± 4.0% vs. 57.5% ± 6.4%; \( p < 0.05 \); Figure 5).
Figure 5. Decrease in infarct size in Tg\textsuperscript{(MLC−CAT)} mice. At day 3 following myocardial infarction, a significant decrease in infarct size was observed in Tg\textsuperscript{(MLC−CAT)} mice as compared to WT mice. Values are mean ± SEM expressed as infarct size/area at risk; \( n = 5–6 \) per group; * \( p < 0.05 \) \( t \)-test.

2.6. Increase in Endothelial Cell Infiltration and Vessel Formation in Tg\textsuperscript{(MLC−CAT)} Mice

To determine the contribution of angiogenesis following myocardial infarction (MI), endothelial cell presence and vessel formation were measured tissue sections following staining with fluorescent Isolectin B4. Data were expressed as either vessels or cells per mm\(^2\) after counting several sections per animal (representative sections in Figure 6A,B). Vessel formation was significantly increased in Tg\textsuperscript{(MLC−CAT)} mice as compared to WT controls, 64.3 ± 10.5 vs. 12.3 ± 4.1, \( p < 0.05 \); Figure 6C). Endothelial cell number was also increased significantly (655.4 ± 111.6 vs. 272.7 ± 26.5; \( p < 0.01 \); Figure 6D).

Figure 6. Increase in endothelial cells and vessels in Tg\textsuperscript{(MLC−CAT)} mice. (A,B) Representative images of infarct tissue stained with isolectin for endothelial cells (red = isolectin; green = autofluorescence; blue = DAPI). White arrows point to vessels, scale bars = 50 µm; (C) Quantitative assessment of numbers of vessels and (D) endothelial cells, were increased in Tg\textsuperscript{(MLC−CAT)} mice as compared to WT mice at 21 days following myocardial infarction. Values are mean ± SEM; \( n = 4 \) per group; * \( p < 0.05 \), ** \( p < 0.01 \) \( t \)-test.
2.7. Increase in Fibrosis in Tg\(^{MLC-CAT}\) Mice

To determine the amount of scar tissue formation following MI, fibrosis (collagen formation) was measured by picrosirius red staining and expressed as percent of left ventricle (LV) area. There was very little fibrosis in sham mice (data not shown), however, Tg\(^{MLC-CAT}\) mice demonstrated an increased level of staining as compared to WT littermates (54.3 ± 9.5 vs. 29.7 ± 5.3; \(p < 0.05\); Figure 7).

**Figure 7.** Increase in fibrosis Tg\(^{MLC-CAT}\) mice. Quantitative assessment of fibrosis (expressed as percent of left ventricle) was increased in Tg\(^{MLC-CAT}\) mice as compared to WT mice. Values are mean ± SEM; \(n = 4–5\) per group; * \(p < 0.05\) \(t\)-test.

2.8. Potential Cytokine/Chemokine Mediators of Changes in Tg\(^{MLC-CAT}\) Mice

To determine potential signaling molecules that could contribute to the phenotype seen in Tg\(^{MLC-CAT}\) mice, we collected protein samples after day 7 and ran an enzyme-linked immunosorbent assay (ELISA) array for mediators of inflammation. Samples from 5 mice per group were pooled and data are expressed as OD450/µg protein. As the data in Table 1 shows, there was an increase in pro-inflammatory cytokine levels in WT mice subjected to MI (TNF\(\alpha\), IL-1\(\beta\), IL-2, MCP1, RANTES). Increases in these cytokines were blunted in Tg\(^{MLC-CAT}\) mice. Moreover, Tg\(^{MLC-CAT}\) mice showed increases in pro-angiogenic and pro-survival growth factors such as VEGF, IGF-1, and FGF. Levels of stem cell mobilizing factors were also increased in Tg\(^{MLC-CAT}\) mice (G-CSF, SCF). Finally, some molecules were either unchanged by MI, or not blunted in Tg\(^{MLC-CAT}\) mice including IFN\(\gamma\), IL-17a, and IL-1\(\alpha\).
Table 1. Levels of cytokines determined by array. Values are OD450/µg protein.

<table>
<thead>
<tr>
<th>Analyte</th>
<th>WT SHAM</th>
<th>WT MI</th>
<th>Tg (MLC−CAT) SHAM</th>
<th>Tg (MLC−CAT) MI</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNFα</td>
<td>1.8</td>
<td>3.1</td>
<td>2.4</td>
<td>2.2</td>
</tr>
<tr>
<td>IGF</td>
<td>1.4</td>
<td>2.4</td>
<td>1.9</td>
<td>3.5</td>
</tr>
<tr>
<td>VEGF</td>
<td>0.3</td>
<td>2.8</td>
<td>2.1</td>
<td>3.9</td>
</tr>
<tr>
<td>IL-6</td>
<td>1.3</td>
<td>2.1</td>
<td>1.9</td>
<td>1.9</td>
</tr>
<tr>
<td>FGF</td>
<td>1.5</td>
<td>2.1</td>
<td>2.4</td>
<td>2.4</td>
</tr>
<tr>
<td>IFN</td>
<td>0.9</td>
<td>1.4</td>
<td>0.8</td>
<td>2.1</td>
</tr>
<tr>
<td>Leptin</td>
<td>0.2</td>
<td>0.3</td>
<td>2.0</td>
<td>2.8</td>
</tr>
<tr>
<td>IL-1α</td>
<td>3.5</td>
<td>2.1</td>
<td>2.7</td>
<td>1.1</td>
</tr>
<tr>
<td>IL-1β</td>
<td>3.1</td>
<td>6.7</td>
<td>4.5</td>
<td>3.6</td>
</tr>
<tr>
<td>G-CSF</td>
<td>2.1</td>
<td>0.6</td>
<td>0.1</td>
<td>0.5</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>2.7</td>
<td>0.0</td>
<td>2.2</td>
<td>0.0</td>
</tr>
<tr>
<td>MCP-1</td>
<td>0.0</td>
<td>0.8</td>
<td>0.0</td>
<td>0.4</td>
</tr>
<tr>
<td>MIP-1α</td>
<td>1.0</td>
<td>0.9</td>
<td>0.0</td>
<td>1.2</td>
</tr>
<tr>
<td>SCF</td>
<td>0.8</td>
<td>1.6</td>
<td>1.9</td>
<td>6.2</td>
</tr>
<tr>
<td>Rantes</td>
<td>0.0</td>
<td>1.6</td>
<td>0.8</td>
<td>0.4</td>
</tr>
<tr>
<td>PDGF</td>
<td>0.0</td>
<td>2.2</td>
<td>0.0</td>
<td>0.4</td>
</tr>
<tr>
<td>IL-17</td>
<td>2.0</td>
<td>2.2</td>
<td>0.8</td>
<td>1.9</td>
</tr>
<tr>
<td>IL-2</td>
<td>0.0</td>
<td>0.6</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>IL-4</td>
<td>0.0</td>
<td>2.4</td>
<td>0.2</td>
<td>0.8</td>
</tr>
<tr>
<td>IL-10</td>
<td>2.1</td>
<td>5.5</td>
<td>3.6</td>
<td>4.1</td>
</tr>
</tbody>
</table>

2.9. Discussion

There are mixed studies on the efficacy of delivered catalase following myocardial infarction. While some studies suggest an acute benefit, others show no improvements in function [9–14,22]. Adding to this controversy, studies of over-expression of catalase show differences depending on the timing of over-expression. When expressed by cardiomyocytes from birth, catalase confers both acute and chronic protection [19]. When an inducible system was used to control timing of expression in cardiomyocytes, different results were obtained that demonstrated the need for temporal control [20]. While both of those studies were done with cardiomyocyte-specific over-expression, no studies have been done to determine the role of myeloid-specific over-expression of catalase on post-infarct healing. The goal of this study was to determine whether myeloid-specific over-expression of catalase improves function following infarction.

MI triggers an inflammatory response which results in activation of cytokine and chemokine cascades, leading to recruitment of the primary responders of myeloid lineage (neutrophils and monocytes/macrophages) to the infarct zone within a day of ischemic injury. These cells carry out phagocytosis and wound debridement to clear dead cells and matrix debris. Pro-inflammatory cytokine/chemokine cascades and excessive production of reactive oxygen species (ROS) are key characteristics of this phase [23–25]. While it is acknowledged that ROS may be required for normal tissue balance and healing, excessive production triggers apoptosis/necrosis, impairs tissue regeneration, and leads to adverse remodeling [3,5,26,27]. It was not surprising therefore, that the current study demonstrated acute reduction in H₂O₂ levels that correlated with increased levels of
catalase. Inflammatory cells responding to the injury were likely present in the heart and seemingly were the main contributors to this finding as shown by catalase activity in CD45<sup>+</sup> cells from the infarcted LV. Interestingly, while H<sub>2</sub>O<sub>2</sub> levels were still decreased at 21 days following injury, catalase levels had fallen back to WT levels. At this 3 week time point, these macrophages and myeloid-lineage cells were likely cleared from the site of injury as we could not detect any by flow cytometry. As H<sub>2</sub>O<sub>2</sub> may also regulate expression of catalase, it is possible that the excessive scavenging of H<sub>2</sub>O<sub>2</sub> led to a refractory decrease in catalase expression and activity [28,29]. Interestingly, while catalase activity was reduced, there was still significant scavenging of H<sub>2</sub>O<sub>2</sub> in myocardial tissue. Measurement of non-catalase peroxidase activity was increased, suggesting possible compensatory upregulation of other H<sub>2</sub>O<sub>2</sub> scavenging enzymes, such as glutathione peroxidases or similar antioxidants.

To determine the effect of this cell-specific scavenging of H<sub>2</sub>O<sub>2</sub> levels on cardiac function, we performed echocardiography at both 7 and 21 days, representing acute and chronic time-points, respectively. Both measurements of ejection fraction and fractional shortening demonstrated significant improvements in LV function at the 7 day time point in Tg<sup>(MLC−CAT)</sup> mice as compared to WT littermates. This is in contrast to our prior studies with catalase over-expression in cardiomyocytes where there was no acute improvement in cardiac function [20]. Tg<sup>(MLC−CAT)</sup> mice also had reduced infarct size, indicating a potential mechanism of cardiomyocyte survival at this early time point. It is quite interesting that over-expression of catalase in cardiomyocytes did not protect the myocytes from acute injury, whereas catalase over-expression in myeloid cells did. Whether this is due to reduced H<sub>2</sub>O<sub>2</sub> directly on cardiomyocytes or reduced negative paracrine factor release as a result of catalase over-expression is not known, and a potential area for future investigation. Indeed, we saw decreased inflammatory cytokine levels in Tg<sup>(MLC−CAT)</sup> mice including TNFα, IL-1β, IL-17, MCP-1, and Rantes. Despite initial improvements in cardiac function, and despite continued scavenging of H<sub>2</sub>O<sub>2</sub>, there was no improvement in chronic cardiac function in Tg<sup>(MLC−CAT)</sup> mice. Once again, this was in stark contrast to our prior study with cardiomyocyte-specific over-expression of catalase where chronic function was improved due to alterations in fibrosis and collagen expression. In the current study, reduction of H<sub>2</sub>O<sub>2</sub> levels did not lead to a decrease in fibrosis, but rather an increase. It is evident that scavenging of H<sub>2</sub>O<sub>2</sub> of catalase may not be the primary factor, but rather the cell type in which it is scavenged. While overall H<sub>2</sub>O<sub>2</sub> levels were decreased in the current study, it is possible that cardiomyocyte H<sub>2</sub>O<sub>2</sub> was normal or even increased, leading to increased collagen deposition. A previous swine study demonstrated similar increased fibrosis in spite of diminished infarct size and improved ejection fraction with peptide delivery following induction of myocardial infarction [30]. It appears that although ventricular function was acutely improved by treatment with a recombinant peptide, the increased fibrosis carried long-term damaging sequelae. One interesting finding in our study was the discovery that Leptin was highly expressed in Tg<sup>(MLC−CAT)</sup> mice, almost 10x greater than WT levels. A recent study found that Leptin delivery can increase cardiac fibrosis in mice via mTOR signaling [31]. Leptin also mediates fibrosis in a variety of other organs and thus may be an important contributor to this response [32–34].

In a prior study of myeloid-specific catalase over-expression during hindlimb ischemia, impaired healing and angiogenesis was seen [21]. This was attributed to defective macrophage recruitment and inflammatory response, as well as disordered angiogenesis. In the current study we saw improved recruitment of endothelial cells and new vessel formation. While the infiltration of inflammatory cells has not been directly compared between myocardial infarction and hindlimb ischemia, it is possible
that the level of cells was much more robust following MI as compared to hindlimb ischemia. Indeed, our cytokine array showed a large increase in G-CSF which may play a role in recruitment of cells. Moreover, we saw no difference in CD45-positive cell recruitment between WT and Tg\(^{MLC-\text{CAT}}\) mice. Additionally, as the heart is much more vascular than muscle, it is possible that increases in local collateral flow as seen in mice could allow for the migration of myeloid-lineage cells to the infarcted region. Investigating potential mechanisms, our cytokine array determined increases in VEGF, FGF, and IGF-1, all of which have been associated with increased angiogenesis and may have contributed to this response. Finally, permanent ligation was chosen as a model as it was similar to the prior study in mouse hindlimbs, as well as a clinically-relevant model. We also performed ischemia-reperfusion studies (30 min of ischemia followed by reperfusion) and saw similar trends in acute protection that was lost long-term with increases in collagen (data not shown). This is quite interesting as it suggests similar contributions or mechanisms of myeloid-derived catalase despite potentially different mechanisms of injury.

3. Experimental Section

3.1. Animals

Transgenic mice over-expressing catalase in myeloid cells (Tg\(^{MLC-\text{CAT}}\)) were created on a C57BL/6J background as described previously [21]. Briefly, human catalase under the control of a myeloid-specific promoter Lysz was exposed by Cre/LoxP mediated excision of a green fluorescent protein and stop codon, allowing for over-expression of catalase only in cells of myeloid lineage. In Tg\(^{MLC-\text{CAT}}\) mice, GFP remains in all non-macrophages and is an internal control for recombination. Control mice used for all experiments, designated as wild-type (WT) mice, were negative littermates. All mice used were males between 8 and 12 weeks.

3.2. MI Model

Permanent ligation of the left anterior descending (LAD) artery was performed under isoflurane anesthesia to create a mouse model of MI in all mice as described previously [20]. Sham animals received thoracotomy and all subsequent procedures without placement of a ligating suture. All experimental protocols were approved by Emory University Institutional Animal Care and Use Committee (protocol DAR-2001731-042415BN valid through 24 April 2015).

3.3. Echocardiographic Studies

Indices of left ventricular function such as EF and FS were measured via two-dimensional (2-D) echocardiography which was performed using a high-resolution imaging system with a 30-MHz imaging transducer (Vevo 770; VisualSonics, Toronto, ON, Canada) as described previously in anesthetized mice [20]. A researcher blinded to genotypes and treatments analyzed the images. Left ventricular end-diastolic dimension (LVDd) and left ventricular end-systolic dimension (LVDs) were measured. These two indices were used to calculate percent fractional shortening (FS%), which quantifies contraction of the ventricular wall (FS% = (LVDd − LVDs)/LVDd × 100%).
3.4. Infarct Size Determination

Infarct size was measured three days after LAD artery ligation. Evans blue (4%, 0.3 mL) was delivered to the left ventricle via the carotid artery. The ventricle was excised and sectioned into 2-mm cross-sectional segments followed by immersion in 1% triphenyl-tetrazolium chloride (TTC). Following overnight incubation in 4% paraformaldehyde, the sections were imaged using a Nikon camera. Infarct size (infarct area/area at risk) was then calculated using Image J software (National Institutes of Health, Bethesda, MD, USA).

3.5. Measurement of $H_2O_2$

Hydrogen peroxide production in heart tissue was measured as described previously using Amplex red assay (Invitrogen, Grand Island, NY, USA) on left ventricular tissue pieces and normalized to wet tissue weight [20].

3.6. Catalase Activity Assay

Catalase activity was assessed in homogenized heart tissue via decomposition of $H_2O_2$ at 240 nm utilizing a plate reader in the presence and absence of 3-amino-1,2,4-triazole (3-AT, a catalase inhibitor) and normalized to protein levels as determined by Bradford assay as previously described [35]. Other peroxidase activity was determined by the 3-AT insensitive fraction.

3.7. CD45 Cell Sorting

Single-cell suspensions were prepared from pooled LV tissues ($n = 3$) of both WT and Tg (MLC\textsuperscript{−}CAT) mice on day 7 following MI. Infarcted hearts were harvested, LV tissue isolated and minced with fine scissors and placed into a cocktail of collagenase I, collagenase XI, DNase I, and hyaluronidase (Sigma-Aldrich, St. Louis, MO, USA) while shaking at 37 °C for 1 h. Cells were then triturated through nylon mesh and centrifuged (15 min, 1500 rpm, 4 °C). Cells were washed once and re-suspended in Hank’s Balanced Salt Solution (with Ca$^{2+}$/Mg$^{2+}$) buffer, blocked with 1% Fetal Calf Serum, and incubated in PE-conjugated anti-mouse CD45 (Invitrogen). Cells were then sorted based on CD45 expression to identify cells of the myeloid lineage, and catalase activity assay performed on protein isolated from both the CD45$^+$ and CD45$^-$ cell populations.

3.8. Collagen Staining

Collagen deposition was determined by Picrosirius red (Sigma-Aldrich) staining, as previously described [20]. Briefly, 5-µm tissue sections were stained with Picrosirius red and imaged using light microscopy. A researcher blinded to genotypes and treatment groups measured total collagen area (areas stained red) and normalized to total LV area, using Matlab™ software (Mathworks, Natick, MA, USA).
3.9. Angiogenesis Staining

Endothelial cell and vessel formation were measured by Isolectin staining as previously described [17]. Briefly, 5-µm tissue sections were stained with Isolectin conjugated to Alexafluor-647 (Invitrogen) and imaged using fluorescent microscopy. Positively stained cells were counted in the infarcted tissue area and reported as either number of vessels or endothelial cells per mm².

3.10. Cytokine Array

Protein homogenates from mice subjected to MI for 7 days were collected and 100 µg were used in a cytokine ELISA array (Signosis, Santa Clara, CA, USA) per manufacturer’s protocol. Pooled protein from 5 animals per group was used to reduce variability and data were expressed as OD450/µg protein.

4. Conclusions

In the current study, over-expression of catalase in myeloid-lineage cells leads to acute protection as evidenced by improvement in ventricular function, diminished levels of H₂O₂, increased catalase activity, increased angiogenesis and diminished infarct size. The lack of further ventricular improvement after 7 days could be attributed to the increase in fibrosis and diminished catalase activity observed at 21 days, though we found compensatory increases in other peroxidases. These data taken together with our previous findings in catalase-specific over-expression, underscore the need for consideration of spatial and temporal signaling in the context of catalase therapy.

Acknowledgments

This work was supported by grant HL094527 from the National Institutes of Health to MED as well as a Merck/United Negro College Fund fellowship to KDP.

Author Contributions

E.B.C., I.S., P.L.C., M.E.B., K.D.P., and M.E.D. performed experiments; E.B.C., I.S., W.R.T., B.C., and M.E.D. analyzed the data; E.B.C., W.R.T., and M.E.D. designed the study; E.B.C., I.S., and M.E.D. wrote and edited the paper.

Conflicts of Interest

The authors declare no conflict of interest.

References


© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).